ReviewEpigenetics2017
Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.
Review in Epigenetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- The role of epigenetic modifications in hematological cancers.Frontiers in oncology · 2026Review
- Mutations in CREBBP and EP300 HAT and Bromo Domains Drive Hypermutation and Predict Survival in GI Cancers Treated with Immunotherapy.Biomedicines · 2025Article
- Unraveling the Epigenetic Landscape of Mature B Cell Neoplasia: Mechanisms, Biomarkers, and Therapeutic Opportunities.International journal of molecular sciences · 2025Review
- Clinical Risk Stratification and Modifiable Risk Factors for Hepatitis B Virus-Related Follicular Lymphoma.ImmunoTargets and therapy · 2025Article
- [Analysis of clinical factors of bendamustine combined with rituximab in the treatment of recurrent follicular lymphoma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- The follicular lymphoma epigenome regulates its microenvironment.Journal of experimental & clinical cancer research : CR · 2022Review
- Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat.OncoTargets and therapy · 2022Review
- Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin's lymphoma.Scientific reports · 2021Article
- DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity.Scientific reports · 2021Article
- EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.Future oncology (London, England) · 2021Article
- Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention.Cancers · 2021Review
- Genetic complexity impacts the clinical outcome of follicular lymphoma patients.Blood cancer journal · 2021Article
- Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma.Frontiers in oncology · 2021Article
- Article
- Establishment and characterization of a novel 'double-hit' follicular lymphoma cell line, FL-SJC.Journal of cellular and molecular medicine · 2020Article
- Dramatic increase in gene mutational burden after transformation of follicular lymphoma into TdTCold Spring Harbor molecular case studies · 2020Article
- Germinal Center Cells Turning to the Dark Side: Neoplasms of B Cells, Follicular Helper T Cells, and Follicular Dendritic Cells.Frontiers in oncology · 2020Review
- Novel treatment approaches and future perspectives in follicular lymphoma.Therapeutic advances in hematology · 2019Review
- KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma.Diagnostic pathology · 2018Article
- Follicular Lymphoma: Past, Present, and Future.Current treatment options in oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
While follicular lymphoma (FL) is exquisitely responsive to immuno-chemotherapy, many patients follow a relapsing remitting clinical course driven in part by a common precursor cell (CPC) population. Advances in next generation sequencing have provided valuable insights into the genetic landscape of FL and its clonal evolution in response to therapy, implicating perturbations of epigenetic regulators as a hallmark of the disease. Recurrent mutations of histone modifiers KMT2D, CREBBP, EP300, EZH2, ARIDIA, and linker histones are likely early events arising in the CPC pool, rendering epigenetic based therapies conceptually attractive for treatment of indolent and transformed FL. This review provides a synopsis of the main epigenetic aberrations and the current efforts in development and testing of epigenetic therapies in this B cell malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.